Loading grant details…
An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection
| Funder | European Commission |
|---|---|
| Recipient Organization | Empe Diagnostics Ab |
| Country | Sweden |
| Start Date | Mar 01, 2021 |
| End Date | Feb 29, 2024 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 969112 |
Grant Description
Tuberculosis (TB) kills more people than any other pathogen-borne illness; yearly, 10M people fall ill and 1.6M die. TB also contributes to a growing existential crisis: the spread of antibiotic resistant bacteria.
Multi-drug-resistant TB is flourishing due to incomplete diagnoses and widespread prescription of ineffective antibiotics. Commercial diagnostics often require equipment in the €12-70K range and are either very slow or incomplete.
As a result, less than one-third of new TB patients undergo strain testing to determine whether antibiotic resistance is present. mfloDx is a low-cost, DNA-based TB diagnostic, similar to home-pregnancy tests. In
All Grantees
Empe Diagnostics Ab
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
